Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypothalamic digoxin-mediated model for Parkinson's disease.

Ravi Kumar Kurup1, Parameswara Achutha Kurup

  • 1Department of Neurology, Medical College Hospital, Trivandrum, Kerala, India. kvgnair@satyam.net.in

The International Journal of Neuroscience
|July 15, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypothalamic digoxin-mediated model for epileptogenesis.

Acta neuropsychiatrica·2016
Same author

Isoprenoid pathway dysfunction in chronic fatigue syndrome.

Acta neuropsychiatrica·2016
Same author

Hypothalamic digoxin, hemispheric chemical dominance and sarcoidosis.

Acta neuropsychiatrica·2016
Same author

A cholesterol and actinide dependent shadow biosphere of archaea and viroids in autoimmune diseases.

Immunobiology·2011
Same author

Familial hypothalamic digoxin deficiency syndrome.

The Journal of neuropsychiatry and clinical neurosciences·2004
Same author

Hypothalamic digoxin-mediated model for trisomy 21.

Pediatric pathology & molecular medicine·2003
Same journal

Thoracic paravertebral nerve block combined with general anesthesia for patients undergoing minimally invasive vertebroplasty: effects on pain and lumbar function.

The International journal of neuroscience·2026
Same journal

Recurrence associated IGFBP2 promotes malignant progression and epithelial mesenchymal transition in glioma cells via the AKT mTOR pathway.

The International journal of neuroscience·2026
Same journal

Decreased miR-1305 expression is associated with tumour invasiveness and poor prognosis in glioma patients.

The International journal of neuroscience·2026
Same journal

Astaxanthin alleviates ischemia-reperfusion injury by regulating the JAK2/STAT3 signaling pathway.

The International journal of neuroscience·2026
Same journal

Clinical efficacy of cryopreserved autologous bone flaps versus titanium plates for cranioplasty: A retrospective comparative study.

The International journal of neuroscience·2026
Same journal

Sericin improves diabetic cognitive impairment in rats by inhibiting TXNIP/NLRP3 neuroinflammation through SIRT1.

The International journal of neuroscience·2026
See all related articles

Parkinson's disease is linked to a dysfunctional isoprenoid pathway, affecting key metabolites like digoxin and ubiquinone. This dysfunction contributes to the disease's development, with a new model suggesting hypothalamic digoxin involvement.

Area of Science:

  • Biochemistry
  • Neuroscience
  • Metabolic pathways

Background:

  • The isoprenoid pathway generates essential metabolites: digoxin (Na(+)-K+ ATPase inhibitor), dolichol (protein N-glycosylation), ubiquinone (antioxidant), and cholesterol (cell membranes).
  • Parkinson's disease (PD) is a neurodegenerative disorder with complex pathophysiology.
  • Understanding metabolic dysregulation in PD is crucial for identifying therapeutic targets.

Purpose of the Study:

  • To investigate alterations in the isoprenoid pathway in Parkinson's disease patients.
  • To explore the consequences of isoprenoid pathway dysfunction on cellular components and biochemical markers in PD.
  • To propose a novel pathogenetic model for PD involving hypothalamic digoxin.

Main Methods:

  • Analysis of plasma and serum metabolites, enzyme activities, and cellular components in Parkinson's disease patients compared to controls.

Related Experiment Videos

  • Measurement of isoprenoid pathway metabolites (e.g., digoxin, dolichol, ubiquinone, cholesterol).
  • Assessment of related biochemical markers including neurotransmitters, glycosaminoglycans, free fatty acids, and oxidative stress indicators.

    • Main Results:

    • Elevated plasma HMG CoA reductase activity, serum digoxin, and dolichol levels were observed in PD.
    • Reduced serum magnesium, RBC membrane Na(+)-K+ ATPase activity, and serum ubiquinone levels were found in PD patients.
    • Significant changes in neurotransmitter levels, glycosaminoglycans, lipid profiles, and oxidative stress markers were documented in PD.

    Conclusions:

    • A dysfunctional isoprenoid pathway is implicated in the pathogenesis of Parkinson's disease.
    • Alterations in isoprenoid metabolites and related biochemical cascades contribute to PD.
    • A hypothalamic digoxin-mediated model is proposed for Parkinson's disease pathogenesis.